The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
We need to step up and partner to be a real leader !!.. look what nautilus is doing ? I’ve said before to look at chemical analysis digital platform like deepmatter . #dmtr . Come on proteome sciences link up with yr Cambridge /Oxford peers so the uk can be a world leader in proteomics ! We need to be at the forefront !
https://www.fiercebiotech.com/biotech/nautilus-emerges-76m-to-become-illumina-proteomics
I see . Yes 1p is a little low .. 3 or 4p should be okay .. that is taking advantage of the long shareholders who have suffered and are trying to promote proteome sciences who only lately seem to be getting more in gear with taking full opportunity of the market
It certainly is ; we just travelled and it cost us a fortune doing these pcr test.. so they are making so much from the one who travels and has to have them; when I went to the clinic they were booming for business and setting up lots of clinic around the country .. this is a really good business to get into and one that is only going to grow IMO .. soooo much money to be made .. abroad the pcr test to come back was horrendous for us in the fact they push the swab too far up . I never want to experience that again
The diagnostics industry is booming and tests are essential for business to function ; they r expensive and so a non brained fir years to come .. this has dropped but will go back up
Why is this down? News regarding Alzheimer’s in the news atm so hopefully we can play our part in this .
FT ARTICLE
https://markets.ft.com/data/announce/full?dockey=1323-14984072-3FM5Q2BOG6N9G068IEARRRMHQ7
Issuance of key TMT® Patent and Introduction of 18plex TMTpro™ Services
Proteome Sciences is pleased to announce the issuance to it of U.S. Patent No. 10,976,321 relating to methods of analysis using isobaric mass tags. This patent, which covers the TMTcalibrator™ workflow, enables enhanced fluid biomarker discovery and single-cell proteomics and forms part of the intellectual property exclusively licensed to Thermo Fisher Scientific by the Company. Commercial users interested in performing any of the methods covered by U.S. Patent No. 10,976,321 or its foreign counterparts should contact the Thermo Fisher Scientific Licensing Team.
The Company is also launching new higher-throughput services using a recently developed, extended range of TMTpro™ reagents that now provide 18 channels, increasing throughput and enabling quantification of 100 samples in only 6 experiments.
Commenting, Dr. Ian Pike, Chief Scientific Officer, said: "These are key developments for the Company as we see increasing demand for our services across the drug-development and academic sectors. U.S. 10,976,321 is a key patent covering our TMTcalibrator™ technology, which is at the heart of our precision medicine efforts. We are updating the technology access program with our exclusive licensee Thermo Fisher Scientific, offering commercial users and providers of contract research services (CROs) an efficient way to obtain licenses to the TMT® patent portfolio where required.
Combined with the extension of TMTpro™ to 18plex, this represents the most powerful proteomics platform to identify and develop biomarkers that are essential to developing personalised medicine through more efficient, large-scale blood biomarker proteomics, as well as enabling the emerging field of single-cell proteomics".
Yes lovely communication and increasing confidence and awareness generated .. excellent progress . I feel we will have a very good year !
Randox webinar tomorrow about QC software if anyone interested
Throughout the webinar, key speaker Margaret Le Roux will highlight the benefits of implementing a quality control software in a laboratory, specifically focusing on the use of sigma metrics, %bias, total error, uncertainty of measurement and other statistical reports.
This discussion will be beneficial for laboratories looking to work more efficiently and effectively. An automated QC software, such as Acusera 24•7, can help to enhance performance assessment, improve QC strategy and meet regulatory requirements.
https://www.randox.com/european-acusera-247-webinar/
Look at the Randox video which has pinpointed key targets for future health diagnostics ..
https://youtu.be/2kPOS1X5NnE
Yes it is
Lol :)
Yes we are waiting .. let’s hope you are cooking another deal
Hayashi , all I can say PRM r the best at what they do :- think of the extent for UK|Europe where we have a base in Frankfurt germany . with medicine and biotechs all companies need fda approval showing proteome interplays to proceed with diseases/medicines. The US proteomics companies are significantly much in the forefront and in the news. I would expect this to go into the early teens and on .. we need more awareness and understand of our unique position in this sector
Yep. We’ve been waiting ! Good luck !
What does it take to make this grow ?? Lots of innovation and unique position but for months n months its been stagnant and depressed . I’ve just kept this as bottom drawer, but it does warm you to know they are expanding , so as the other poster says keep adding and your long standing patience will eventually be rewarded. Let’s hope we can get above 5p soon. Good luck all
What a lovely day !
I think stay a while longer ! We are so undervalued abdca sector that is so vital , so inherent to diagnostics /medical development , also lovely to see new posters here as I’ve been prm advocate for a while .. keep it up !
Check out the website , and hopefully they will take heed and do more investor awareness PR on what they are R working on not just for business leads but for general awareness /understanding them . So far they are on the right track after a long stint of silence. Quarter1 should be fantastic IMO